Rajesh Ambasudhan,
Research Assistant Professor,
Sanford-Burnham Medical Research Institute
Rajesh Ambasudhan is an accomplished stem cell researcher working in the neuroscience area. He was trained under renowned stem cell biologist Prof. Sheng Ding at The Scripps Research Institute (now at UCSF). Dr. Ambasudhan has experience for over a decade in working with hESCs) and human somatic stem cells. He and his former mentor Sheng Ding were among the first few in the world to adapt Yamanaka’s hiPSC technology and have made seminal contributions to this area, particularly in developing small molecule-based innovations to this technology (Nature Methods 2009, Cell Stem Cell 2010, Cell Res. 2014). Moreover, he is among the pioneers who invented the technique by which human skin cells can be directly converted to functionally mature neurons using a microRNA technique (Cell Stem Cell 2011). As a Sanford-Burnham Medical Research Institute (SBMRI) faculty, he has been developing human “disease-in-a-dish” models of neurodegenerative diseases. Of note is his use of this model in discovering the critical role of an aberrant MEF2-PGC1a pathway in Parkinson’s disease using isogenic stem cells (Cell, 2013), a work he conducted in collaboration with Prof. Rudolf Jaenisch at M.I.T.
Use of Isogenic Human iPSCs to Elucidate Redox-mediated Pathways to Parkinson’s, Alzheimer’s, and other Neurodegenerative Disorders
Friday, 16 January 2015 at 16:00
Add to Calendar ▼2015-01-16 16:00:002015-01-16 17:00:00Europe/LondonUse of Isogenic Human iPSCs to Elucidate Redox-mediated Pathways to Parkinson’s, Alzheimer’s, and other Neurodegenerative DisordersPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Dr. Ambasudhan uses human stem cell based "disease-in-a dish" models to study neurodegenerative disorders. Recently, his laboratory developed isogenic patient-derived hiPSC models of Parkinson's disease, to complement transgenic mouse models, and characterized certain redox-mediated protein post-translational modifications that may be an early event in the disease pathogenesis. These studies also led to screens for drugs that can thwart these modifications and may be developed as potential disease-modifying therapies. The recent findings will be presented in the seminar.
Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2015-01-16 16:00:002015-01-16 17:00:00Europe/LondonUse of Isogenic Human iPSCs to Elucidate Redox-mediated Pathways to Parkinson’s, Alzheimer’s, and other Neurodegenerative DisordersPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California, USASELECTBIOenquiries@selectbiosciences.com
